Pfizer Inc., which makes results of the first quarter before the opening of the stock market Tuesday, probably will focus on a recent acquisition, promising data on some experimental drugs and efforts to improve its portfolio of business as CEO Ian Readwhich resumed in December.
WHAT TO WATCH for: Pfizer, the world largest drugmaker, is more in the firearm to find ways to maintain revenue and profits with the largest expiration month drug patent fair history. Lipitor, the Hunter of cholesterol from 12 billion dollars a year, loses U.S. patent protection on 30 November and already has a generic competition in some small markets.
Investors will be watching see if Pfizer maintains its revenue planned for 2012, when generic competition will eat Lipitor sales. Pfizer already reduced by $ 2.2 billion to approximately $ 64,25 billion and said that it will reduce the research of 2012 by $ 1.5 billion, or about $ 8.25 billion. This is a category where the level or an increase in funding is preferred.
Pfizer, the creator of the Viagra impotence pill and pain treatment Lyrica, is also injured by pressure on the pharmaceutical industry together: the weakness of the global economy, higher drug rebates required the redesign of the health of the U.S. and pricing pressure from European governments.
Probable executives will update their progress in the reduction of fees by their target of $ 4 billion to $ 5 billion per year since the purchase of Wyeth to 68 billion dollars in October 2009.
Analysts will look for updates on the progress made in reviewing the Pfizer and Wyeth research programs, products and companies to keep. Pfizer recently made a gesture expected, saying that he will sell his business for the manufacture of capsule of $ 2.4 billion. Pfizer plans to use to buy back shares and possibly perform certain transactions.
Last month, Pfizer bought King Pharmaceuticals Inc., which makes pain medications and other products of $ 3.6 billion. Last week, Pfizer has said that he will continue business increased in the huge Chinese market with its largest distributor, Shanghai Pharmaceutical Co. Ltd., including them stimulate the promotion of Prevnar.
This month, the Food and Drug Administration advisers recommended approving two drugs against cancer of Pfizer, Afinitor and Sutent, for treating Advanced Pancreatic Tumors and pancreatic tumors that cannot be removed surgically, respectively. SUTENT is approved for the treatment of tumors in four different bodies, but failed in the test against lung and prostate cancer.
Company executives cannot fail to discuss the three main experimental drug research news.
But Pfizer of the summer with problems elsewhere, including running within the time limits of regulators on other drugs.
WHY it is important: in the past few years, Pfizer repeatedly had promising experimental drugs fail in stages of tests, including what had been a drug successor awaited to Lipitor, despite research spending heavy. That and the poor company stock performance for the past four years, led to the Pfizer Board to evict the predecessor to Read.
Since the acquisition of Wyeth and furious cost-cutting increased temporarily the bottom line. But Pfizer needs to develop or buy rights to multiple big new drugs to resist expiration Lipitor patent.
What is expected: analysts surveyed by FactSet expect to benefit by action of 58 cents and revenues of Max billion.
QUARTER last year: a year ago, Pfizer posted benefit net per share of 25 cents, or 60 cents excluding restructuring costs and other and revenues of $ 16.75 billion.
No comments:
Post a Comment